**Mycobacterium tuberculosis**

Rv1152 is a Novel GntR Family Transcriptional Regulator Involved in Intrinsic Vancomycin Resistance and is a Potential Vancomycin Adjuvant Target

Jie Zeng1,*, Wanyan Deng1,*, Wenmin Yang1, Hongping Luo1, Xiangke Duan1, Longxiang Xie1, Ping Li1, Rui Wang1, Tiwei Fu1, Abualgasim Elgaili Abdalla2,3 & Jianping Xie1

Novel factors involved in *Mycobacteria* antibiotics resistance are crucial for better targets to combat the ever-increasing drug resistant strains. *Mycobacterium tuberculosis* Rv1152, a novel GntR family transcriptional regulator and a promising vancomycin adjuvant target, was firstly characterized in our study. Overexpression of Rv1152 in *Mycobacterium smegmatis* decreased bacterial susceptibility to vancomycin. Moreover, a deficiency in MSMEG_5174, an Rv1152 homolog made *M. smegmatis* more sensitive to vancomycin, which was reverted by complementing the MSMEG_5174 deficiency with Rv1152 of *M. tuberculosis*. Rv1152 negatively regulated four vancomycin responsive genes, namely genes encoding the ribosome binding protein Hsp, small unit of sulfate adenylyltransferase CysD, L-lysine-epsilon aminotransferase Lat, and protease HtpX. Taken together, Rv1152 controls the expression of genes required for the susceptibility to vancomycin. This is the first report that links the GntR family transcriptional factor with vancomycin susceptibility. Inhibitors of Rv1152 might be ideal vancomycin adjuvants for controlling multi-drug resistant Mycobacterial infections.

Tuberculosis, caused by *Mycobacterium tuberculosis* (*M. tuberculosis*) infection, remains the second highest pandemic disease with formidable rate of morbidity and mortality worldwide1, particularly in developing countries and HIV co-infected population despite decade’s implementation of TB control programs2. The emergence of multidrug-resistant strains of *M. tuberculosis*3, extensively drug resistance (XDR), even totally drug resistance (TDR) cases of TB (MDR-TB) was reported in 2013. The genus *Mycobacterium* includes both pathogenic and saprophytic species that are able to survive under environmental stresses, including oxidative and genotoxic stress, hypoxia, nutrient starvation and multiple antibiotics7,8. Transcriptional regulation plays an important role in the bacterial response to environmental stresses. The GntR family of bacterial regulators is named after the *Bacillus subtilis* transcription regulator GntR, the first characterized transcriptional GntR-type repressor required for gluconate metabolism9,10. This holds true for the GntR family of transcriptional regulators, with around 2000 members in both bacterial and archaea genomes9,11. The proteins belong to GntR family share a characteristic conserved N-terminal domain with winged helix-turn-helix that is involved in DNA binding, which can be easily recognized by a Conserved Domain Database (CDD) search12. GntR consists of six subfamilies differing in C-terminal signaling domains involved in

---

1 Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Beibei, Chongqing 400715, China. 2 Department of Clinical Microbiology, College of Medical Laboratory Sciences, Omdurman Islamic University, Omdurman, Khartoum, Sudan. 3 These authors contributed equally to this work. Correspondence and requests for materials should be addressed to J.X. (email: georgex@swu.edu.cn)
the effector binding\(^{11}\), namely FadR, HutC, MocR, YtrA, AraR and PlmA\(^{13,14}\). GntR regulators are defined as a part of specific subfamily\(^{15}\). The structures of FadR alone and in complex with its effector and operator DNA have been recently determined\(^{16-19}\), before no structural information is available for other three subfamilies of GntR-like regulators. GntR regulators in \(M.\text{tuberculosis}\)\(^{20}\) and \(M.\text{smegmatis}\)\(^{21}\) are just to only bioinformatically predicted, while lacking experimental evidences for the proposed functions.

In this study, we identified a novel \(M.\text{tuberculosis}\) GntR family regulator, Rv1152, which can alter cell wall permeability of \(M.\text{smegmatis}\) to acid and surface stress and play an important in vancomycin loss of susceptibility through negatively regulating the genes responsive to vancomycin. In brief, \(M.\text{smegmatis}\) overexpressed \(M.\text{tuberculosis}\) Rv1152 (MS_Rv1152) was more resistant to vancomycin than \(M.\text{smegmatis}\) harboring the vector only (MS_Vec), while the MSMEG_5174 (the homologous gene of Rv1152 in \(M.\text{smegmatis}\)) deletion mutant (\(\Delta\text{MSMEG}_5174\)) was more sensitive to vancomycin than the wild type \(M.\text{smegmatis}\). More importantly, the susceptibility phenotype of \(\Delta\text{MSMEG}_5174\) to vancomycin can be complemented by the Rv1152 (\(\Delta\text{MSMEG}_5174\)::Rv1152). Several vancomycin responsive genes were down regulated in \(M.\text{smegmatis}\) overexpressed Rv1152 strain, while the expression of the same set of vancomycin responsive genes was up regulated in homologous gene MSMEG_5174 knock out strains. The genes regulated by Rv1152 are responsible for the sensitivity of \(M.\text{smegmatis}\) to vancomycin. These data suggest that Rv1152 involved in the loss of susceptibility to vancomycin through negatively regulating the expression of vancomycin responsive genes.

### Material and Methods

#### Strains, Plasmids and Primers

\(M.\text{smegmatis}\) mc\(^{2}\)155 strains were preserved by the Institute of Modern Biopharmaceuticals. \(Escherichia\ coli\) DH5\(\alpha\) strain used for gene clone was grown at 37 °C in Luria-Bertani (LB) broth or on LB agar with appropriate antibiotics. \(M.\text{smegmatis}\) was grown at 37 °C in Middlebrook (MB) 7H9 liquid medium or on MB 7H10 agar supplemented with 0.2% (w/v) glucose, 0.5% (v/v) glycerol and 0.05% (v/v) Tween 80. Hygromycin (100 \(\mu\)g/ml) was added when required. All strains were stored with sterile 20% glycerol at −80°C for further use. The genomic DNA of \(M.\text{tuberculosis}\) H37Rv was provided by Chongqing Pulmonary Hospital. The bacterial strains and plasmids used in this study are described in Table 1. All the PCR primers were synthesized by BGI (Shenzhen, Guangdong, China) and the sequences of primers are listed in Table 2.

#### Construction of overexpression strains

The full length of Rv1152 gene and several vancomycin responsive genes was amplified from \(M.\text{tuberculosis}\) H37Rv genome DNA using the specific gene primer pairs (Table 2). For Rv1152, The PCR product and the plasmid pALACE were digested with \(BamHI\) and \(Clai\) to generate the recombinant pALACE-Rv1152. For the vancomycin responsive genes in \(M.\text{tuberculosis}\) and their homologous genes in \(M.\text{smegmatis}\): including Rv0251c (MSMEG_0424), Rv1285 (MSMEG_4979), Rv0563 (MSMEG_1134) and Rv3290c (MSMEG_1764), the PCR products were ligated into the plasmid pALACE digested by \(BamHI\) and \(NdeI\). All plasmids were electroporated into \(M.\text{smegmatis}\), a non-pathogenic, fast-growing mycobacterium that, serves as a surrogate model organism to study genes functions of the virulent \(M.\text{tuberculosis}\). The electroporated recombinant \(M.\text{smegmatis}\) strains were plated on Middlebrook (MB) 7H10 agar containing 50 \(\mu\)g/ml hygromycin after in vitro growth in MB 7H9 liquid medium for 3 hour. The positive strains were further verified by Western blot.

#### Western blot and subcellular localization

Generally, the acetamide-induced recombinant MS_Rv1152 and MS_Vec were sonicated. The whole lysates were centrifuged at the speed of 3,000 × g for 5 min at 4 °C to remove un-lysed cells and cell debris. The supernatants were ultra-centrifuged at the speed of 27,000 × g for 40 min at 4 °C. After ultra-centrifugation, the pellets were considered the cell wall fraction, and the supernatants were supposed to be cell membrane and cytosol fractions. The pellets were further suspended in 1 × PBS. Equal amounts of protein from pellet and supernatant fractions were subjected to Western blotting for analyzing the

### Table 1. The list of strains and plasmids used in the study.

| Strains     | Description of strains                                      | Source               |
|-------------|------------------------------------------------------------|----------------------|
| WT          | Wild type \(M.\text{smegmatis}\) mc\(^{2}\)155 strain      |                      |
| MS_Vec      | \(M.\text{smegmatis}\) with transformed with vector pALACE | This study            |
| MS_Rv1152   | \(M.\text{smegmatis}\) with transformed with vector pALACE_Rv1152 | This study            |
| \(\Delta\text{MSMEG}_5174\) | Parent strain \(M.\text{smegmatis}\) with an in-frame MSMEG_5174 deletion mutation from the genome. | This study            |
| \(\Delta\text{MSMEG}_5174::Rv1152\) | MSMEG_5174 mutate strain transformed with a inducible vector pALACE_Rv1152 | This study            |
| E. coli DH5a | Strain used in vector proliferation                       | Invitrogen           |
| E. coli_Rv1152 | Strain DH5a transformed with plasmid pALACE used for vector proliferation. | This study            |
| Plasmids    | Description of Plasmids                                   |                      |
| pALACE      | A replicative plasmid used for gene expression in \(M.\text{smegmatis}\) and conferring hygromycin (hyg) resistance |                      |
| pJV53       | A replicative plasmid expressing two phase recombinases and conferring kanamycin (Km) resistance |                      |
plated onto MB 7H10 agar containing hygromycin, the bacteria were counted after 3 days of incubation. The duration of 3, 6 and 9 h, respectively. After SDS and acidic treatment, the recombinant strains were diluted and detected as a cytoplasmic control by an anti-His mouse primary antibody (TIANGEN, China).

Table 2. Primers used in the study.

| Primer        | Description                      | Sequence of primers (5′-3′)          |
|---------------|----------------------------------|--------------------------------------|
| Rv1152-F1     | Construct recombinant MS_Rv1152 strain | GGAATCCGCGCCAGCCGCGCTCAGCCG         |
| Rv1152-R1     |                                    | AAGCTTCAAGGGCGAGCCGCGCCCA           |
| KO-F1         | Amplify MSMEG_5174 upstream sequence | TATGGATCCTACGTGGAAGCTGCGG          |
| KO-R1         |                                    | GTTGCTACGATTCACTAGTCGTCCGG          |
| KO-F2         | Amplify MSMEG_5174 downstream sequence | TCGGCTAGAGGGCGGTTCCTTCGTCACACCCCTGAGTAGTGG |
| KO-R2         |                                    | AAGCTTCCGCTGGGTGTTGACCTGGA          |
| Lat-F1        | Construct recombinant MS_Lat strain | TGCTTCATCGCGGGAACCCATCCA           |
| Lat-R1        |                                    | CGAAGCGAGACCCACATGGCGACCATCA        |
| Rv0251c-F1    | Construct recombinant MS_Rv0251c strain | GACGGATCCATGAAACAATCTCGCA        |
| Rv0251c-R1    |                                    | CGGGCCATAGCTACTCTGTYGAT            |
| Rv1285-F1     | Construct recombinant MS_1285 strain | CTGGTCGGATCCATGGCAATAAC          |
| Rv1285-R1     |                                    | CTGGTCGGATCCATGGCAATAAC            |
| Rv0563-F1     | Construct recombinant MS_0563 strain | GGAGAGACGGATCCATGACCTGCGG         |
| Rv0563-R1     |                                    | GGAATTCATTCATGACGCCGCGCCCAT       |
| MSMEG_0424-F1 | Construct recombinant MSMEG_0424 overexpressing strain | AGGGGGATCCATGACGGCCGCGATGAA      |
| MSMEG_0424-R1 |                                    | GGCGGGTTTTATATGTTCACCGGCTCTCG     |
| MSMEG_4979-F1 | Construct recombinant MSMEG_4979 overexpressing strain | AAGGGATCCATGGCGGCGGCGAGCGAG      |
| MSMEG_4979-R1 |                                    | GCCTGGCCAATGTCAGAAATACCCC          |
| MSMEG_1134-F1 | Construct recombinant MSMEG_1134 overexpressing strain | GACGGATCCATGACGTTGAATCC          |
| MSMEG_1134-R1 |                                    | GGCATATGCAGATGATGCTGATCAGTCC       |

expression of Rv1152. Native M. smegmatis GroEL2, which contains a string of endogenous histidines24, was detected as a cytoplasmic control by an anti-His mouse primary antibody (TIANGEN, China).

Construction of the genetic deletion and complementation strains. An in-frame deletion of the gene MSMEG_5174 (the homolog of M. tuberculosis Rv1152), a GntR-family response regulator of M. tuberculosis was constructed using Xer site-specific recombination25. Two DNA fragments, comprising 600 and 700 bp (including the first 50 bp and the last 50 bp of the gene, respectively), were amplified from the genome of M. tuberculosis (including the first 50 bp and the last 50 bp of the gene, respectively), were amplified from the genome of M. smegmatis (MSMEG_5174). The resulting DNA fragment was purified and introduced by recombineering into M. smegmatis derivative containing pJV53, a replicative plasmid expressing two phage recombinases and conferring kanamycin resistance26,27. Two hygromycin-resistant colonies were isolated and tested by PCR for the correct integration of the excisable cassette into the chromosome (not shown). Subsequently, they were grown for 10 generations in the absence of hygromycin and kanamycin to allow excision of the hygromycin cassette and the loss of pJ/V33. Hygromycin and kanamycin-sensitive colonies were finally recovered at the expected frequency. One of them was analyzed in parallel with a colony of the wild-type parental strain by PCR with primers flanking the region used for the recombination. BGI sequencing confirmed the successful construction of the knockout strain M. smegmatis (△MSMEG_5174).

For the complementation strains, the Rv1152 complemented M. smegmatis strains (△MSMEG_5174::Rv1152) were constructed by integrating M. tuberculosis homolog Rv1152 into the chromosomes of the respective deletion strains. Briefly, the Rv1152 gene was first cloned into a pALACE vector, and the recombinant plasmid pALACE_Rv1152 was transformed into the respective M. smegmatis mutant strains. The complementation strain was selected on 7H10 medium (complemented with 0.2% glycerol) containing 50 μg/mL hygromycin and the hygromycin-resistant strains were selected and further confirmed by using Western blot.

In vitro growth of the bacteria under acid and surface stresses. Growth patterns of the two recombinant mycobacteria were examined according to previously described procedures28. Briefly, M. smegmatis was grown overnight in Middlebrook 7H9 medium (complemented with 0.05% Tween 80 and 0.2% glycerol). Recombinant MS_Vec and MS_Rv1152 were grown in presence of surface stress and acidic stress. For surface stress, acetamide-induced MS_Vec and MS_Rv1152 were treated with 0.05% SDS for 1, 2, 3 and 4 h. For acidic stress, HCl was added into the 7H9 medium and adjusted to pH 4. MS_Rv1152 and MS_Vec were exposed for duration of 3, 6 and 9 h, respectively. After SDS and acidic treatment, the recombinant strains were diluted and plated onto MB 7H10 agar containing hygromycin, the bacteria were counted after 3 days of incubation.

The MIC determinations for antibiotics. Seven antibiotics including vancomycin (Van), norfloxacin (Nor), ciprofloxacin (Cip), ofloxacin (OFI), erythromycin (Ery),isoniazid (INH), and rifampicin (Rif) were used in this study. Growth patterns of the wild type M. smegmatis strain (WT), the gene deletion mutant (△
MSMEG_5174), and complementation strains (△MSMEG_5174::Rv1152), the overexpression strain (MS_Rv1152) and the control strain (MS_Vec) were measured according to the procedures described previously with minor modification\textsuperscript{23,29}. The MICs of antibiotics were determined by using serial two-fold dilution of the antibiotics in 7H9 medium as previously described\textsuperscript{26}. Briefly, wells of a 96 well microtiter plate were filled with 100 μl of 7H9 medium. The required highest antibiotic concentration was prepared and 200 μl were added to the first vial. This was serially diluted to halve the concentration by mixing with equal volume of bacterial culture in the subsequent wells till second to the last well. Last vial was the control without antibiotics. The \textit{M. smegmatis} strains were grown in replicates in 7H9 medium to an OD\textsubscript{600} of 0.8, 1% of original bacteria was inoculated to 100 μl of the prepared culture with or without antibiotics. MIC values of each antibiotic were determined as drug concentration that inhibited bacterial growth by at least 99%.

\textbf{Determination of bactericidal effect of antibiotics.} To determine mycobacterial growth curves and the effect of antibiotics, \textit{M. smegmatis} strains including WT, MS_Vec, MS_Rv1152, △MSMEG_5174, and △MSMEG_5174::Rv1152 were grown overnight in Middlebrook 7H9 broth (supplemented with 0.05% Tween80 and 0.2% glycerol). Hygromycin was not added in the 7H9 medium when assaying antibiotics resistance of all strains. When cells entered a stationary growth phase (OD\textsubscript{600} between 0.8–1.0), each culture was 10-fold diluted in 100 μl of fresh 7H9 broth containing the indicated concentration of each antibiotic. The cultures were then allowed to grow further at 37°C with shaking at 110 rpm. After 24 hour treatment with these antibiotics with different concentrations, the bacteria were diluted by 10-fold and plated into 7H10 agar medium. The bacterial numbers were counted after 3 days culture. The medium without any antibiotics serves as the control to make sure the normal growth of bacteria.

\textbf{RT-PCR detection of the gene transcription.} Isolation of mRNA and cDNA preparation were performed from wild type strains (WT), MSMEG_5174 deletion mutants (△MSMEG_5174), \textit{M. smegmatis} harboring pALACE (MS_Vec) and Rv1152 overexpression \textit{M. smegmatis} strains (MS_Rv1152). RT-PCR was used to compare the transcriptional levels of genes expression using gene specific primers and the real-time PCR analysis was subsequently carried out according to previously described procedures\textsuperscript{31}. The reactions were performed in a RT-PCR machine (Bio-Rad IQ5) under the following thermocycling parameters: 95°C for 5 min and 40 cycles at 95°C for 30s, 60°C for 30s and 72°C for 30s. Amplification specificity was assessed using melting curve analysis. Gene expression levels were normalized to the levels of \textit{sigA} gene transcription. Average relative expression levels and standard deviations were determined from three independent experiments. All the gene specific primers used for RT-PCR were listed in the Table 1S.

\textbf{Statistical analysis.} The experiments were performed in triplicate. Differences between groups were analyzed by using Prism 6 and Student’s t test. ***P < 0.001, **P < 0.01, *P < 0.05, means ± SEM from at least three biological replicates.

\textbf{Results} \textit{M. smegmatis} overexpressing Rv1152 showed altered response to stresses. To study the function of Rv1152, we constructed the recombinant \textit{M. smegmatis} harboring pALACE_Rv1152 (MS_Rv1152) and vector only (MS_Vec). Rv1152 gene was successfully amplified from the \textit{M. tuberculosis} genome by using gene specific primers (Fig. 1A). Western blot showed the presence of the expressed 14kDa his-tagged in MS_Rv1152 but not in MS_Vec (Fig. 1B), suggesting that Rv1152 was successfully expressed in \textit{M. smegmatis}. Rv1152 localized to both cell wall and cytoplasm of \textit{M. smegmatis}: the target proteins were found in cell wall and cytoplasm of MS_Rv1152, but not in MS_Vec while the cytoplasm marker GroEL2 of \textit{M. smegmatis} was detected in both MS_Rv1152 and MS_Vec (Fig. 1C).

The ability of \textit{M. tuberculosis} to survive within the host requires resistance to various physiological and environmental stresses. Within granuloma, \textit{M. tuberculosis} is able to persist for years even under severe stresses such as hypoxia, nutrient limitation, reactive oxygen and nitrogen intermediates, low pH, alveolar surfactants, and free fatty acids\textsuperscript{32}. However, bacterial factors that enhanced their survival under harsh condition remain poorly understood. Mycobacterial responses to cell surface stress are of particular interest for understanding the pathogenesis of \textit{M. tuberculosis} and its susceptibility to antibiotics\textsuperscript{33}. The recombinant MS_Rv1152 showed more cell death than MS_Vec when the bacteria were exposed to acid stress (Fig. 2A). Although there was a rapid decrease in the bacterial numbers for all tested strains exposed to the detergent SDS, in comparison with MS_Vec, MS_Rv1152 was more tolerant to SDS: the percentage survival values were 5% for the MS_Rv1152 and 1.5% for the MS_Vec. The greater tolerant of the MS_Rv1152 to SDS was verified when bacterial survival was tested after 1 hour when incubation with SDS (Fig. 2B). These results suggest that the overexpression of Rv1152 in \textit{M. smegmatis} modified the \textit{M. smegmatis} response to surface and acid stress.

\textit{Rv1152} confers \textit{M. smegmatis} reduced susceptibility to vancomycin. Vancomycin (Van), the last-resort antibiotics against infections caused by meticillin-resistant \textit{Staphylococcus aureus} (MRSA)\textsuperscript{34}, is a glycopeptide blocking the transpeptidation and nascent peptidoglycan synthesis. Van, in combination with lipid biosynthesis targeting antibiotic, was recently found more effective in killing multidrug-resistant (MDR) and extensively-drug resistant (XDR) \textit{M. tuberculosis}\textsuperscript{35}. Interestingly, Rv1152 decreased susceptibility of \textit{M. smegmatis} to vancomycin, as the MIC of MS_Rv1152 for vancomycin is 80 μg/ml while MS_Vec is 20 μg/ml, there is no significant difference in MIC when using Cip, OFL, Nor, Ery, INH, and Rif (Table 3). In comparison with MS_Vec group, MS_Rv1152 is less susceptible to vancomycin even at the concentrations of 5μg/ml. No bacteria of MS_Vec were detected on the plate supplemented with 20 μg/ml vancomycin (Fig. 3A). In addition, the obvious
difference in survival of bacteria between MS_Rv1152 and MS_Vec were detected after treatment with vancomycin with various concentrations of for 24 h: there was about $1.3 \times 10^5$ (CFU/ml) of MS_Rv1152 survived while no colony of MS_Vec can be detected when 80 $\mu$g/ml vancomycin was used (Fig. 3B). These data suggest that overexpression of Rv1152 in \textit{M. smegmatis} contributes to reduced susceptibility to vancomycin.

The isogenic deletion of MSMEG_5174 increased susceptibility to vancomycin. In order to further study the role of Rv1152 in vancomycin susceptibility, the homologous gene of Rv1152 in \textit{M. smegmatis}, MSMEG_5174, was deleted (△MSMEG_5174). As shown in Fig. 4A, the sizes of the fragments amplified from the two colonies were consistent with expectations (300 bp for the mutant and 657 bp for the WT). The fragment amplified from the mutant bacteria was sequenced to verify the correctness of the excision: as expected, a copy of the DIF sequence flanked by two \textit{Bgl}II restriction sites was found in the correct position, replacing the 247 central nucleotides of the target gene (Fig. 4B). Rv1152 was successfully expressed in △MSMEG_5174 after transformation Rv1152 gene into △MSMEG_5174 strain (Fig. 4C). The MSMEG_5174 gene knockout strain is more sensitive to vancomycin than the wild type \textit{M. smegmatis}: most bacteria of △MSMEG_5174 were inhibited when using vancomycin at the concentration of 5 $\mu$g/ml and this sensitive phenotype was complemented in △MSMEG_5174::Rv1152 strain. No significant difference between WT and △MSMEG_5174 was detected when using other antibiotics (Table 4). The same result was reiterated when the strains were treated with different concentration of vancomycin (Fig. 5): with the increasing of the concentration of vancomycin, MSMEG_5174 deleted mutant are more sensitive than the WT strain, no bacteria of △MSMEG_5174 strains were detected, while there were obvious WT bacteria survived when using vancomycin at the concentration of 40 $\mu$g/ml.

\textbf{Rv1152 negatively regulates the expression of vancomycin responsive genes.} \textit{M. smegmatis} has been widely used as a surrogate model bacterium to study the gene regulation and signal transduction mechanism of pathogenic mycobacteria\textsuperscript{23,36}. The vancomycin responsive genes that transcriptionally regulated by Rv1152, together with their corresponding homologous genes in \textit{M. smegmatis} were summarized in Table 5. The genome-wide regulator-DNA interaction network of \textit{M. tuberculosis H37Rv} has shown that 68 genes are regulated by Rv1152\textsuperscript{37}. Global transcriptome has shown that several \textit{M. tuberculosis} genes are differentially regulated upon exposure to vancomycin\textsuperscript{38}. To define the molecular mechanisms of the role of Rv1152 in vancomycin susceptibility, we tested whether vancomycin responsive genes are regulated by Rv1152. In comparison with WT strains, four genes including heat stress induced ribosome binding protein (MSMEG\textsubscript{0424}), L-lysine-epsilon aminotransferase (MSMEG\textsubscript{1764}), small unit of sulfate adenylyltransferase (MSMEG\textsubscript{4979}), and protease transmembrane protein heat shock protein (MSMEG\textsubscript{1134}) were up-regulated in △MSMEG\textsubscript{5174} strain, such expression pattern was restored in the Rv1152 complementary strain (Fig. 6A). The relative expression of these four genes to \textit{sigA} was also up regulated after the homologous gene MSMEG\textsubscript{5174} in \textit{M. smegmatis} was knocked out (Fig. 6B), suggesting that Rv1152 negatively regulated the expression of these four genes. There was no significant difference for other genes listed in the Table 5 among WT, △MSMEG\textsubscript{5174} and △MSMEG\textsubscript{5174::Rv1152}
strains (data not shown). We further identified Rv1152 inhibited the expression of these four target genes in *M. smegmatis* (Fig. 6C). These data suggest that Rv1152 represses the expression of the four vancomycin responsive genes.

**Rv1152 regulated genes affect susceptibility to vancomycin.** To determine whether Rv1152 regulated genes affect susceptibility to vancomycin, the recombinant strains expressing vancomycin responsive genes from *M. tuberculosis* and their homologous genes from *M. smegmatis* were constructed (Fig. 1S). The MIC for vancomycin of recombinant strains MS_Lat, MS_Rv1285, MS_Rv0251 and MS_Rv0563 was lower than MS_Vec, similar results were obtained from the *M. smegmatis* homologous gene recombinant strains (Table 2S). We have recently identified a lysine-epsilon aminotransferase (Lat) encoded by Rv3290c was involved in persister formation. Interestingly, *M. smegmatis* overexpressing Lat exhibited more susceptibility to vancomycin than the wild type carrying the control vector –MS_Lat showed a greater bacterial cell death than MS_Vec (Fig. 7A). After 48 hour treatment with high concentration vancomycin, no bacteria was detectable (detection limit of 100 bacteria/ml) for MS_Lat while many colonies were recovered with MS_Vec control (Fig. 7B). These results demonstrate that overexpression of Lat in *M. smegmatis* make the host strain more sensitive to vancomycin. Overexpressing of another three vancomycin responsive genes (Rv_1285, Rv_0251, and Rv0563) from *M. tuberculosis* and their homologous genes (MSMEG_4979, MSMEG_0424, and MSMEG_1134) from *M. smegmatis* decreased susceptibility of host bacteria to vancomycin (Fig. 8). These data suggest that Rv1152 negatively regulated genes are responsive to vancomycin, resulting in decreased susceptibility of host bacteria to vancomycin.

**Figure 2.** Effect of Rv1152 overexpression on acid and surface stress tolerance. (A) Survival of recombinant MS_Vec and MS_Rv1152 after 0, 3, 6 and 9 h treatment with low pH (pH = 4). (B) Survival of recombinant MS_Vec and MS_Rv1152c after exposure to 0.05% sodium dodecyl sulfonate (SDS) for 0, 1, 2, and 4 hours.

| Antibiotics (µg/ml) | MS_Vec | MS_Rv1152 |
|--------------------|--------|-----------|
| Van                | 20     | 80        |
| INH                | 8      | 8         |
| Rif                | 16     | 16        |
| Ery                | 64     | 64        |
| Nor                | 32     | 16        |
| OFL                | 0.25   | 0.25      |
| CIP                | 0.25   | 0.25      |

*Table 3. The response of MS_Vec and MS_Rv1152 to antibiotics.*
Figure 3. Overexpression of Rv1152 in M. smegmatis decreases vancomycin susceptibility. (A) Ten-fold serial dilutions of MS_Rv1152 and MS_Vec were plated onto 7H10 agar supplemented with 0, 5, 10, and 20 μg/ml vancomycin. The plate without any antibiotic served as the control to confirm the normal growth of bacteria. (B) MS_Rv1152 and MS_Vec were spotted on the 7H10 plate without any antibiotic after 24 hour treatment with 0, 5, 10, 20, 40, 80 μg/ml vancomycin, respectively. The bacteria numbers were counted after 3 days of incubation.

Figure 4. Construction of the △MSMEG_5174 and △MSMEG_5174::Rv1152 strains. (A) confirmation of MSMEG_5174 gene knockout by PCR amplification from WT and △MSMEG_5174 strains. M, Marker DL10000; 1, PCR band from △MSMEG_5174 strain; 2, PCR band from WT strain. (B) A map of the sequencing of PCR amplification products and DNAMAN alignment showing 28 bp DIF in △MSMEG_5174 strain. (C) Western blot showed that the Rv1152 gene was expressed in △MSMEG_5174 strain.
| Antibiotics (μg/ml) | WT | ΔMSMEG_5174 | ΔMSMEG_5174::Rv1152 |
|-------------------|----|-------------|------------------|
| Van               | 20 | 5           | 20               |
| INH               | 64 | 32          | 64               |
| Rif               | 16 | 8           | 16               |
| Ery               | 64 | 128         | 128              |
| Nor               | 32 | 32          | 32               |
| OFL               | 0.25 | 0.25     | 0.25             |
| CIP               | 0.25 | 0.25      | 0.25             |

Table 4. The response of WT, ΔMSMEG_5174 and ΔMSMEG_5174::Rv1152 to antibiotics.

Figure 5. Susceptibility of ΔMSMEG_5174 strains to vancomycin. Ten-fold serial dilutions of wild type, ΔMSMEG_5174 and ΔMSMEG_5174::Rv1152 were plated on Middlebrook 7H10 with different concentration of vancomycin. Numbers of the bacteria were counted after 3 days incubation.

| Gene     | Name     | Homologous Product |
|----------|----------|--------------------|
| Rv0824c  | desA1    | MSMEG_5773          |
| Rv0251c  | hsp      | MSMEG_0424          |
| Rv0516c  | htpX     | MSMEG_0586          |
| Rv0563   | htpX     | MSMEG_1134          |
| Rv0580c  | lat      | MSMEG_1764          |
| Rv2688c  | rv2688c  | MSMEG_1502          |
| Rv3862c  | whiB6    | MSMEG_0051          |
| Rv1285c  | cysD     | MSMEG_4979          |
| Rv1153c  |          | MSMEG_5173          |
| Rv1151c  |          | MSMEG_5175          |

Table 5. The genes responsive to vancomycin.
Discussion

The unusual ability of *M. tuberculosis* to persist for years within human host, and the requirement for lengthy antibiotic combination regimens to eliminate drug sensitive strains are hallmarks of this recalcitrant pathogen. Its prolonged chronic infection requires the expression of a complex array of genetic determinants, including those involved in secondary metabolism, cell wall processes, stress responses, and signal transduction. Transcriptional regulators are well-established key players for the mycobacteria adaptation, such as two-component regulatory systems, stress-responsive sigma factors including *sigB*, *sigE*, and *sigH*. We expressed GntR-like family transcriptional regulator Rv1152 in *M. smegmatis* and found that Rv1152 localized to both cell wall and cytoplasm. The up-regulation of Rv1152 after 96 h of starvation prompted us to test whether recombinant MS_Rv1152 will affect the permeability to these antimicrobial factor, the growth characteristics of MS_Vec and MS_Rv1152 under acid and surface stress were analyzed, as the transcription of *sigB* depends on *SigE* under physiological conditions and following exposure to SDS. Our data identified that overexpression of Rv1152 in *M. smegmatis* has no
effect on the bacterial growth in standard culture conditions (Fig. 2S), while Rv1152 can modify the response of \( \textit{M. smegmatis} \) to different stresses. Rv1152 enhanced tolerance of \( \textit{M. smegmatis} \) to SDS, but it sensitized bacteria to acid stress.

**Figure 7.** Overexpression of Lat in \( \textit{M. smegmatis} \) sensitizes vancomycin susceptibility. (A) Log change in colony-forming units (CFU)/ml, from time zero, of MS_Vec (Log CFU/ml = 7.2999) and MS_Lat (Log CFU/ml = 7.4926) after treatment for 24 hours with different concentrations of vancomycin. (B) Killing curves of MS_Lat and MS_Vec upon 50\( \mu \)g/ml vancomycin exposure for the indicated times. ♦untreated MS_Vec; ▲untreated MS_Lat; ▲antibiotic-treated MS_Vec; ●antibiotic-treated MS_Lat.

**Figure 8.** Overexpression of genes regulated by Rv1152 sensitizes vancomycin susceptibility. (A) Ten-fold serial dilutions of MS_Vec, MS_Rv1285, MS_Rv0251c, MS_Rv0563 plated onto 7H10 agar medium supplemented with 2.5 and 10\( \mu \)g/ml vancomycin, respectively. (B) Ten-fold serial dilutions of MS_Vec, MS_MSMEG_0424, MS_MSMEG_4979 and MS_MSMEG_1134 plated onto 7H10 agar medium supplemented with 2.5 or 5\( \mu \)g/ml vancomycin, respectively. The plate without any antibiotic served as the control to confirm the normal growth of bacteria.
Mycobacterial responses to stress are of particular interest to understand the pathogenesis of *M. tuberculosis* and its sensitivity and reaction to antibiotics. The detailed pathways, signals, regulatory responses and molecular interactions are not yet well understood, despite the existence of 190 in silico predicted transcription regulators in the *M. tuberculosis* genome. The genus *Mycobacterium* includes both pathogenic and saprophytic species that are able to survive under environmental stresses, including oxidative and genotoxic stress, hypoxia, nutrient starvation, and multiple antibiotics. We suspected that Rv1152 might be involved in vancomycin susceptibility since the expression of Rv1152 was up-regulated under vancomycin exposure. In congruent with our expectation, the expression of Rv1152 in *M. smegmatis* was shown to be up-regulated under vancomycin loss of susceptibility. The MSMEG_5174 knock-out strain (ΔMSMEG_5174) was constructed, MSMEG_5174, the homolog of Rv1152, bearing the signature of the YtrA subfamily member. In comparison with the parental strain, MSMEG_5174 gene knock out has little effect on the growth of *M. smegmatis* (Fig. 3S). ΔMSMEG_5174 is more susceptible to vancomycin than the parental *M. smegmatis*, suggesting the involvement of MSMEG_5174 in the tolerance to vancomycin. In addition, the response of Rv1152 complemented ΔMSMEG_5174 strain to vancomycin was restored to the level of parental *M. smegmatis*. Taken together, our data indicate that Rv1152 plays an important role in vancomycin loss of susceptibility.

*M. tuberculosis* transcriptome alteration in response to vancomycin was mined for genes regulated by Rv1152 and involved in vancomycin loss of susceptibility. We found that the expression of four vancomycin responsive genes were down-regulated in Rv1152 overexpression *M. smegmatis*, including ribosome binding protein (MSMEG_0424), small unit of sulfate adenylyltransferase (MSMEG_4979), L-lysine-epsilon aminotransferase (MSMEG_1134), and protease HtpX (MSMEG_1764), respectively. Their expression was also increased in response to vancomycin treatment. The expression of these four genes was increased in ΔMSMEG_5174, and the complementary strains ΔMSMEG_5174::Rv1152 showed the restored levels of transcription for these four genes. We further found these four genes are responsible for susceptibility to vancomycin. In summary, our data demonstrate that *M. tuberculosis* Rv1152 plays a role in vancomycin loss of susceptibility via negatively regulating the expression of genes responsive to vancomycin. Vancomycin is a robust glycopeptide antibiotic against multiple drug resistant clinical strains. This is the first report of *Mycobacteria* GntR family transcriptional factor involved in vancomycin loss of susceptibility. Further discovery of inhibitors against Rv1152 may provide good advatnages for vancomycin or other antibiotics targeting the cell wall biosynthesis.

References

1. Dye, C., Williams, B. G., Espinal, M. A. & Raviglione, M. C. Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis. *Science* **295**, 2042–2046, doi: 10.1126/science1063814 (2002).
2. Corbett, E. L. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Arch Intern Med* **163**, 1009–1021, doi: 10.1001/archinte.163.9.1009 (2003).
3. Matteelli, A. et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. *Expert Rev Anti-Infect. Med* **5**, 857–871, doi: 10.1586/14787210.5.5.857 (2007).
4. Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* **368**, 1573–1586, doi: 10.1016/S0140-6736(06)69573-1 (2006).
5. Velayati, A. A. et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. *Chest* **136**, 420–425, doi: 10.1378/chest.08-2427 (2009).
6. Shah, N. S. et al. Worldwide emergence of extensively drug-resistant tuberculosis. *Emerg Infect Dis* **13**, 380–387, doi: 10.3202/eid13030.61400 (2007).
7. Zahr, T. C. & Deretic, V. Reactive nitrogen and oxygen intermediates and bacterial defenses: unusual adaptations in Mycobacterium tuberculosis. *Antioxid Redox Sig** **3**,** 141–159, doi: 10.1089/1523086027563292 (2002).
8. Hingley-Wilson, S. M., Sambandamurthy, V. K. & Jacobs, W. R., Jr. Survival perspectives from the world’s most successful pathogen, Mycobacterium tuberculosis. *Nat Immunol* **4**, 949–955, doi: 10.1038/nn981 (2003).
9. Haydon, D. J. & Guest, J. A new family of bacterial regulatory proteins. *FEBS Microbiol Lett* **63**, 291–295 (1991).
10. Fujita, Y. & Fujita, T. The glutamate operon gnt of Bacillus subtilis encodes its own transcriptional negative regulator. *P Natl Acad Sci USA* **84**, 4524–4528 (1987).
11. Rigali, S., Deroaux, A., Giannotta, F. & Durant, J. Subdivision of the helix-turn-helix GntR family of bacterial regulators in the *FadR*, HutC, and YtrA subfamilies. *J Biol Chem* **277**, 12507–12515, doi: 10.1074/jbc.M110968200 (2002).
12. Marchler-Bauer, A. et al. CDD: a Conserved Domain Database for protein classification. *Nucleic Acids Res* **33**, D192–196, doi: 10.1093/nar/gkf069 (2005).
13. Rigali, S. et al. Subdivision of the helix-turn-helix motif of a transcription factor gene family. *J Bacteriol* **185**, 4315–4325 (2003).
14. Lee, M. H., Scherer, M., Rigali, S. & Golden, J. W. PlmA, a new member of the GntR family, has plasmid maintenance functions in *Mycobacterium tuberculosis*. *Nat Immunol* **4**, 949–955, doi: 10.1038/nn981 (2003).
15. Casali, N., White, A. M. & Riley, L. W. Regulation of the Mycobacterium tuberculosis mce operon. *J Bacteriol* **188**, 441–449, doi: 10.1128/JB.188.2.441-449.2006 (2006).
16. van Aalten, D. M., DiRusso, C. C., Knudsen, J. & Wiemenga, R. K. Crystal structure of FadR, a fatty acid-responsive transcription factor with a novel acyl coenzyme A-binding fold. *EMBO J* **19**, 5167–5177, doi: 10.1093/emboj/19.19.5167 (2000).
17. Xu, Y., Heath, R. J., Li, Z., Rock, C. O. & White, S. W. The FadR:DNA complex. *Transcriptional control of fatty acid metabolism in Escherichia coli*. *J Biol Chem* **276**, 17373–17379, doi: 10.1074/jbc.M010952000 (2001).
18. Youssuf, S., Angara, R., Vindal, V. & Ranjan, A. Rv494 is a starvation-response, auto-regulatory FadR-like regulator from *Mycobacterium tuberculosis*. *Microbiology* **161**, 463–476, doi: 10.1099/mic.0.000017 (2015).
19. Biswas, R. K. et al. Identification and characterization of Rv0494: a fatty acid-responsive protein of the GntR/FadR family from *Mycobacterium tuberculosis*. *Microbiology* **159**, 913–923, doi: 10.1099/mic.0.06654-0 (2013).
20. Vindal, V., Ranjan, S. & Ranjan, A. In silico analysis and characterization of GntR family of regulators from Mycobacterium tuberculosis. *Tuberculosis* **87**, 242–247, doi: 10.1016/j.tube.2006.11.002 (2007).
21. Vindal, V., Suma, K. & Ranjan, A. GntR family of regulators in *Mycobacterium smegmatis*: a sequence and structure based classification. * BMC Genomics* **8**, 289, doi: 10.1186/1471-2164-8-289 (2007).
22. Gupte, R. & Parish, T. Electroporation of *Mycobacteria*. *J Vis. Exp.* doi: 76110.3791/761 (2008).
Transcriptional Regulator Involved in Intrinsic Vancomycin Resistance and is a Potential Vancomycin Adjuvant: Zeng, J.

The authors declare no competing financial interests.

Supplementary information

Acknowledgements

This work was supported by National Natural Science Foundation [grant numbers 81371851, 81511120001, 81071316, 81271882, 81301394], New Century Excellent Talents in Universities [grant number NCET-11-0703], National Megaprojects for Key Infectious Diseases [grant numbers 2008ZX10003-006], Excellent Ph.D. thesis fellowship of Southwest University [grant number 20114YJG123104], and The undergraduates teaching reform program [grant number 2013JY201]. The experiments were conceived and designed by J.Z., W.D. and J.X. Most experiments conducted by J.Z. and Y.X. The undergraduates teaching reform program [grant number 2013JY201].

Author Contributions

The experiments were conceived and designed by J.Z., W.D. and J.X. Most experiments conducted by J.Z. and W.D., they contributed equally to this paper. W.Y., H.L., X.D., P.L., R.W., T.F. and A.E.A. performed several experiments. This paper was written by J.Z., W.D. and J.X. All authors have read and approved the manuscript.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zeng, J. et al. Mycobacterium tuberculosis Rv1152 is a Novel GntR Family Transcriptional Regulator Involved in Intrinsic Vancomycin Resistance and is a Potential Vancomycin Adjuvant Target. Sci. Rep. 6, 28002; doi: 10.1038/srep28002 (2016).